New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in ...
Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.
Clinical Trials Arena on MSN
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint
"Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Allure on MSN
I Thought It Was Acne. Turns Out, It Was Lupus.
But it’s an important detail, along with the fact that I’ve been a beauty journalist for nearly seven years—which means I know my skin, and I know when something is off. So when a spot arrived in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback